[{"address1": "321 Harrison Avenue", "address2": "Suite 900", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 949 2643", "website": "https://www.monterosatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 133, "companyOfficers": [{"maxAge": 1, "name": "Dr. Markus  Warmuth M.D.", "age": 53, "title": "President, CEO & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 924600, "exercisedValue": 0, "unexercisedValue": 2041632}, {"maxAge": 1, "name": "Dr. Filip  Janku M.D., Ph.D.", "age": 50, "title": "Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 713200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Champoux", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John C. Castle Ph.D.", "age": 53, "title": "Chief Data & Information Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sharon  Townson Ph.D.", "age": 49, "title": "Chief Scientific Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Funderburk", "title": "Senior VP and Head of IR & Strategic Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip  Nickson J.D., Ph.D.", "age": 45, "title": "Chief Business & Legal Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Magnus  Walter DPHIL", "title": "Senior Vice President of Drug Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Dunn", "age": 58, "title": "Vice President & Corporate Controller", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.94, "open": 7.04, "dayLow": 6.88, "dayHigh": 7.34, "regularMarketPreviousClose": 6.94, "regularMarketOpen": 7.04, "regularMarketDayLow": 6.88, "regularMarketDayHigh": 7.34, "beta": 1.3, "forwardPE": -4.4565907, "volume": 539590, "regularMarketVolume": 539590, "averageVolume": 2782570, "averageVolume10days": 1329050, "averageDailyVolume10Day": 1329050, "bid": 7.09, "ask": 7.14, "bidSize": 400, "askSize": 800, "marketCap": 436814944, "fiftyTwoWeekLow": 3.21, "fiftyTwoWeekHigh": 12.4, "priceToSalesTrailing12Months": 29.169613, "fiftyDayAverage": 8.1636, "twoHundredDayAverage": 5.949975, "currency": "USD", "enterpriseValue": 227878640, "floatShares": 38209578, "sharesOutstanding": 61436700, "sharesShort": 8404331, "sharesShortPriorMonth": 11152201, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.1368, "heldPercentInsiders": 0.0070499997, "heldPercentInstitutions": 0.90608, "shortRatio": 5.61, "shortPercentOfFloat": 0.2499, "impliedSharesOutstanding": 61436700, "bookValue": 3.347, "priceToBook": 2.1242905, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -119389000, "trailingEps": -1.78, "forwardEps": -1.5, "enterpriseToRevenue": 15.217, "enterpriseToEbitda": -1.882, "52WeekChange": 0.14144742, "SandP52WeekChange": 0.25443196, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GLUE", "underlyingSymbol": "GLUE", "shortName": "Monte Rosa Therapeutics, Inc.", "longName": "Monte Rosa Therapeutics, Inc.", "firstTradeDateEpochUtc": 1624541400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e1526429-092c-3bce-8f14-de475e92b666", "messageBoardId": "finmb_690261281", "gmtOffSetMilliseconds": -18000000, "currentPrice": 7.11, "targetHighPrice": 20.0, "targetLowPrice": 11.0, "targetMeanPrice": 16.0, "targetMedianPrice": 15.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 242186000, "totalCashPerShare": 3.942, "ebitda": -121073000, "totalDebt": 43698000, "quickRatio": 5.83, "currentRatio": 6.033, "totalRevenue": 14975000, "debtToEquity": 21.269, "revenuePerShare": 0.221, "returnOnAssets": -0.28425, "returnOnEquity": -0.61228, "freeCashflow": -47188876, "operatingCashflow": -57292000, "grossMargins": 1.12033, "operatingMargins": -2.87836, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-02"}]